Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Growth Rate of the Hypoparathyroidism Market?

The market for hypoparathyroidism has seen robust expansion in the past few years. The market, which was projected at $0.95 billion in 2024, is anticipated to reach $1.03 billion in 2025 with an 8.6% compound annual growth rate (CAGR). This substantial increase during the historic period can be traced back to the growth in the number of thyroid surgeries, enhanced awareness about hypoparathyroidism, a climb in post-surgical complications, expanding demand for supplements of calcium and vitamin D, and an amplified emphasis on managing endocrine disorders.

What Growth Rate Is Forecasted for the Hypoparathyroidism Market by 2029?

The market for hypoparathyroidism is projected to experience significant expansion in the coming years, with forecasts predicting an increase to $1.42 billion by 2029, representing a compound annual growth rate (CAGR) of 8.3%. The upcoming growth can be linked to the increased uptake of recombinant parathyroid hormone therapies, more funds being directed towards hypoparathyroidism research, improvements in healthcare infrastructure, a growing older population susceptible to endocrine conditions, and heightened initiatives for awareness and early detection. The period under forecast is set to witness major trends like progress in parathyroid hormone therapies, cutting-edge diagnostic methods for hypoparathyroidism, production of sustained-release calcium supplements, breakthroughs in minimally invasive thyroid surgery, and progress in patient monitoring technologies.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24565&type=smp

Which Key Companies Are Shaping the Future of the Hypoparathyroidism Market?

Major companies operating in the hypoparathyroidism market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co Inc., AbbVie Inc., Sanofi S.A., Novartis AG, GlaxoSmithKline plc , Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Cipla Limited , Lupin Limited, Torrent Pharmaceuticals Ltd., Eagle Pharmaceuticals Inc., BridgeBio Pharma Inc., Ascendis Pharma A/S, Extend Biosciences Inc., Entera Bio Ltd.

Which Factors Are Driving Demand in the Hypoparathyroidism Industry?

The growth of the hypoparathyroidism market is foreseen to be driven by the rise in thyroid cancer incidences. Thyroid cancer occurs when abnormal cells multiply in the thyroid gland, creating a noticeable lump in the neck. The rise in thyroid cancer cases is attributed to improvements in diagnostic imaging technologies. These technologies facilitate the early and frequent detection of small thyroid nodules, even when they don’t cause symptoms. The progression of thyroid cancer exacerbates hypoparathyroidism due to increased requirements for thyroid surgeries. These surgeries can unintentionally harm the parathyroid glands, causing a calcium imbalance and a persistent shortage of hormones, which necessitates the need for long-term disease management strategies. For example, data from the US-based non-profit organization, ‘the American Cancer Society’, showed that the number of new thyroid cancer cases rose to 44,020 in 2025, up from 43,720 in 2023. Hence, the growth of the hypoparathyroidism market is being propelled by the escalating thyroid cancer incidences.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=24565&type=smp

How Is the Hypoparathyroidism Market Segmented by Several Divisions?

The hypoparathyroidism market covered in this report is segmented –

1) By Treatment: Hormone Replacement Therapy, Adjunctive Therapies

2) By Type: Hormone Replacement Therapy, Calcium And Vitamin D Supplements, Emerging Therapies

3) By Route Of Administration: Oral, Parenteral

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

5) By End User: Hospitals, Specialty Clinics, Homecare Settings

Subsegments:

1) By Hormone Replacement Therapy: Recombinant Parathyroid Hormone, Parathyroid Hormone Analogues, Calcimimetics, Calcium And Vitamin D Supplements

2) By Adjunctive Therapies: Magnesium Supplements, Phosphate Binders, Other Supportive Therapies

What are the Emerging Market Trends Driving the Growth of the Hypoparathyroidism Industry?

Leading corporations in the hypoparathyroidism market are directing their efforts towards the creation of products based on advanced technology, such as transition technology, in order to improve treatment efficiency and enhance patient results. TransCon (Transient Conjugation) technology is being utilized for the development of these products as it aids in optimized drug delivery. Ascendis Pharma A/S, a biopharmaceutical firm based in Denmark, for instance, introduced YORVIPATH (palopegteriparatide), its second product based on TransCon technology, in Germany and Austria in January 2024. This product aims to address chronic hypoparathyroidism in adults by maintaining physiological PTH levels over a 24 hour period, with its once-daily administration.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/hypoparathyroidism-global-market-report

Which Regions Are Driving Growth in the Hypoparathyroidism Market?

North America was the largest region in the hypoparathyroidism market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hypoparathyroidism market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=24565

This Report Delivers Insight On:

1. How big is the hypoparathyroidism market, and how is it changing globally?

2. Who are the major companies in the hypoparathyroidism market, and how are they performing?

3. What are the key opportunities and risks in the hypoparathyroidism market right now?

4. Which products or customer segments are growing the most in the hypoparathyroidism market?

5. What factors are helping or slowing down the growth of the hypoparathyroidism market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model